LAG-3

melanoma

Biotech

ASCO: Regeneron's Opdualag rival records 61% response rate

At ASCO, Regeneron will make the case for its LAG-3 inhibitor combo in advanced melanoma as a rival to Bristol Myer Squibb’s Opdualag.

Gabrielle Masson May 25, 2023 6:00pm

stage curtains

New Merck lymphoma data could help patients without options

May 26, 2022 5:00pm

close-up of money

LAG-3-focused Immutep secures cash, plots new trial push

Jun 21, 2021 7:10am